You are here

Article Text

Article menu

Download PDFPDF

Oral Presentation
Concurrent session 1: global challenges
LO-003 Prevalence of remission according to physician and patient and level of agreement in a real-world multicenter lupus registry
  1. Julia Martínez-Barrio1,
  2. José María Pego Reigosa2,
  3. Isabel Castrejón1,
  4. María Galindo-Izquierdo3,
  5. Esther Uriarte-Isacelaya4,
  6. Elena Aurrecoechea Aguinaga5,
  7. Natalia Mena Vazquez6,
  8. Irene Altabas2,
  9. José Carlos Rosas Gómez de Salazar7,
  10. Silvia Gómez Sabater8,
  11. Mónica Ibáñez Barcelo9,
  12. Vicente Torrente Segarra10,
  13. F Javier Narváez García11,
  14. Clara Sangüesa Gómez12,
  15. Joan Calvet Fontova13,
  16. Mercedes Freire González14,
  17. Clara Moriano Morales15,
  18. Carlota Iñiguez16,
  19. Eva Gloria Tomero Muriel17,
  20. Ana Pérez Gómez18,
  21. José Luis Andreu Sánchez19,
  22. M Jesús García-Villanueva20,
  23. Tatiana Cobo21,
  24. Gema Bonilla Hernán22,
  25. Nuria Lozano Rivas23,
  26. Loreto Horcada24,
  27. Carlos Montilla Morales25,
  28. Francisco Javier Toyos Sáenz de Miera26,
  29. Lorena Expósito27,
  30. María Esther Ruiz Lucea28,
  31. José Eloy Oller29,
  32. Ángela Pecondón Español30,
  33. Ricardo Blanco Alonso31,
  34. Sergio Machín32,
  35. Eva Salgado33,
  36. Irene Carrión Bárbera34,
  37. Raúl Menor Almagro35,
  38. Jaime Calvo Alen36,
  39. Alejandro Muñoz Jiménez37,
  40. Jorge Fragio Gil38 and
  41. Iñigo Rúa-Figueroa Fdez de Larrinoa39
  1. 1Rheumatology, Hospital General Universitario Gregorio Marañón, Spain
  2. 2Rheumatology, Hospital Meixoeiro, Spain
  3. 3Rheumatology, Hospital 12 de Octubre, Spain
  4. 4Rheumatology, Hospital Universitario Donostia, Spain
  5. 5Rheumatology, Hospital de Sierrallana, Spain
  6. 6Rheumatology, Carlos Haya (Málaga), Spain
  7. 7Rheumatology, Hospital Marina Baixa, Spain
  8. 8Rheumatology, Hospital General Universitario de Alicante, Spain
  9. 9Rheumatology, Hospital Universitari Son Llàtzer, Spain
  10. 10Rheumatology, Hospital de Sant Joan Despí Moisès Broggi/Consorci Sanitari Integral (CSI), Spain
  11. 11Rheumatology, Hospital Universitario de Bellvitge, Spain
  12. 12Rheumatology, Hospital Universitario Germans Trias i Pujol, Spain
  13. 13Rheumatology, Consorci Corporació Sanitària Parc Taulí, Spain
  14. 14Rheumatology, Complejo Hospitalario Universitario de A Coruña (CHUAC), Spain
  15. 15Rheumatology, Complejo Asistencial Universitario de León, Spain
  16. 16Rheumatology, Hospital Lucus Augusti (Anterior Xeral-Calde), Spain
  17. 17Rheumatology, Hospital Universitario La Princesa, Spain
  18. 18Rheumatology, Hospital Universitario Principe de Asturias, Spain
  19. 19Rheumatology, Hospital Universitario Puerta de Hierro, Spain
  20. 20Rheumatology, Hospital Universitario Ramón y Cajal, Spain
  21. 21Rheumatology, Hospital Infanta Sofia, Spain
  22. 22Rheumatology, Hospital Universitario La Paz, Spain
  23. 23Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Spain
  24. 24Rheumatology, Complejo Hospitalario de Navarra, Spain
  25. 25Rheumatology, Hospital Cínico Universitario de Salamanca, Spain
  26. 26Rheumatology, Hospital Virgen de la Macarena, Spain
  27. 27Rheumatology, Hospital Universitario de Canarias, Spain
  28. 28Rheumatology, Hospital Universitario de Basurto, Spain
  29. 29Rheumatology, Hospital Universitario Dr. Peset, Spain
  30. 30Rheumatology, Hospital Universitario Miguel Servet, Spain
  31. 31Rheumatology, Hospital Universitario Marqués de Valdecilla, Spain
  32. 32Rheumatology, Complejo Hospitalario Universitario Insular de Gran Canarias, Spain
  33. 33Rheumatology, Complejo Hospitalario De Orense, Spain
  34. 34Rheumatology, Hospital del Mar, Spain
  35. 35Rheumatology, Hospital Jerez de la Frontera, Spain
  36. 36Rheumatology, Hospital Universitario de Araba, Spain
  37. 37Rheumatology, Hospital Universitario Virgen del Rocío, Spain
  38. 38Rheumatology, Hospital La Fe, Spain
  39. 39Rheumatology, Hospital Universitario de Gran Canaria Doctor Negrín, Spain

Abstract

Background To investigate the prevalence and level of agreement between remission according to physician and patient criteria and to evaluate the impact of remission on HRQoL in patients with SLE.

Methods Prospective study of patients included in RELESSER-PROS, a multicenter register of SLE patients, protocol previously described.1 Remission according to physician was defined in agreement with DORIS 2021 criteria.2 Remission according to patient was defined as SLAQ (Systemic Lupus Activity Questionnaire) question 1 with no flare in the last 3 months (score 0).

Patients were classified in three groups according to remission status (DORIS, SLAQ, both). Level of agreement was assessed using kappa statistics, considered acceptable if kappa>0.60.

Results 1102 patients, with a follow-up of at least 2 years (data from 3 visits available) were included. Patient characteristics according remission status at baseline are presented in the table 1. At baseline, remission by DORIS was present in 16.1%, by SLAQ 16.7% and 2.45% by both. Remission by DORIS was more frequent among patients with higher education, on immunosuppressant/biological therapy and patients with history of hospitalization; remission by SLAQ was more frequent among women, obese patients, and those on antimalarials (p<0.05). Symptoms reported in patients who considered themselves in remission were mainly cutaneous and articular (53.3%). Mean SLEDAI in patients on remission by SLAQ was 3.28 (3.78). Patients in remission by DORIS had significantly better results in patient reported outcomes measured by EQ-5D and LIT (p<0.05). Level of agreement in remission according to physician and patient was 78.04% (K=0.061) at baseline, 63.39% (K=0.039), and 62.73% (K=0.099) in year 2 and 5. Kappa level of agreement was low.

Conclusions Our results reflect low level of agreement between physician and patients in terms of remission status with increasing disagreement in the follow-up. Patients in remission by DORIS shows better results in EQ-5D and LIT.

View this table:
Abstract LO-003 Table 1

Patient characteristics according remission status at baseline

References

  1. Rúa-Figueroa I, et al. Reumatol Clin. 2014;10(1):17–24.

  2. van Vollenhoven RF, et al. Lupus Sci Med. 2021;8(1):e000538.

  • remission
  • health-related quality of life
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/lupus-2023-KCR.3

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.